SCHEMBL2025311

SCHEMBL2025311

CCCCCCc1ccccc1C(C)C(C)c1ccc(O)c(C(C)C(C)c2ccccc2CCCCCC)c1C(C)C(C)c1ccccc1CCCCCC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYSLTR2 Q9NS75 8/20 0.46
▸ CYSLTR1 Q9Y271 8/20 0.46
▸ LIPG Q9Y5X9 1/20 0.44
▸ TYR P14679 2/20 0.42
▸ BID P55957 3/20 0.42
▸ MCL1 Q07820 3/20 0.42
▸ BCL2L1 Q07817 2/20 0.42
▸ BAK1 Q16611 2/20 0.42
▸ KAT8 Q9H7Z6 2/20 0.42
▸ PPARG P37231 1/20 0.42
▸ PPARA Q07869 1/20 0.42
▸ EP300 Q09472 1/20 0.42
▸ KAT2A Q92830 1/20 0.42
▸ KAT2B Q92831 1/20 0.42
▸ KAT5 Q92993 1/20 0.42
▸ SAE1 Q9UBE0 1/20 0.42
▸ MEN1 O00255 1/20 0.40
▸ TP53 P04637 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ ALOX5 P09917 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2023168 1.00 CYSLTR2 (0.46) CYSLTR2CYSLTR1LIPGTYRBID
SCHEMBL2018806 1.00 CYSLTR2 (0.46) CYSLTR2CYSLTR1LIPGTYRBID
SCHEMBL2023177 1.00 CYSLTR2 (0.46) CYSLTR2CYSLTR1LIPGTYRBID
SCHEMBL2021339 1.00 CYSLTR2 (0.46) CYSLTR2CYSLTR1LIPGTYRBID
SCHEMBL2024316 0.99 CYSLTR2 (0.44) CYSLTR2CYSLTR1LIPGTYRBID
SCHEMBL2020279 0.94 CYSLTR2 (0.39) CYSLTR2CYSLTR1LIPGTYRBID
SCHEMBL1843604 0.90 BID (0.49) CYSLTR2CYSLTR1LIPGBIDMCL1
SCHEMBL1845694 0.90 BID (0.49) CYSLTR2CYSLTR1LIPGBIDMCL1
SCHEMBL1842544 0.90 BID (0.49) CYSLTR2CYSLTR1LIPGBIDMCL1
SCHEMBL1843997 0.90 BID (0.49) CYSLTR2CYSLTR1LIPGBIDMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110160476-A1 N-Substituted Carbamic Acid Ester Production Method and Isocyanate Production Method Using the N-Substituted Carbamic Acid Ester ASAHI KASEI CHEMICALS CORPORATION (JP) 2011-06-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160476-A1 N-Substituted Carbamic Acid Ester Production Method and Isocyanate Production Method Using the N-Substituted Carbamic Acid Ester ALKBH3, CPS1, APEH CYSLTR2 3669/4885CYSLTR1 3698/4885LIPG 1612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback